Sandoz: UBS raises target price
(CercleFinance.com) - UBS confirms its buy recommendation on the Sandoz share, raising its target price for it by about 10% to E39.
5 (from E36) following the announcement of its H1 2024 results.
"1H results were mixed, but we see extent of biosimilar beat as reason to turn more positive", UBS says.
On interim publication, Sandoz announces that it has raised its revenue growth forecast to a 'mid-to-high' single-digit percentage at constant exchange rates, and has reinforced its confidence in a core EBITDA margin of around 20%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
5 (from E36) following the announcement of its H1 2024 results.
"1H results were mixed, but we see extent of biosimilar beat as reason to turn more positive", UBS says.
On interim publication, Sandoz announces that it has raised its revenue growth forecast to a 'mid-to-high' single-digit percentage at constant exchange rates, and has reinforced its confidence in a core EBITDA margin of around 20%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.